BR112019005825A2 - vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer - Google Patents
vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncerInfo
- Publication number
- BR112019005825A2 BR112019005825A2 BR112019005825-7A BR112019005825A BR112019005825A2 BR 112019005825 A2 BR112019005825 A2 BR 112019005825A2 BR 112019005825 A BR112019005825 A BR 112019005825A BR 112019005825 A2 BR112019005825 A2 BR 112019005825A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- cancer
- treating
- enveloped virus
- modified enveloped
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616365.1A GB201616365D0 (en) | 2016-09-27 | 2016-09-27 | Non-genetic modification of enveloped viruses |
| GB1616365.1 | 2016-09-27 | ||
| PCT/EP2017/072366 WO2018059896A1 (en) | 2016-09-27 | 2017-09-06 | Non-genetic modification of enveloped viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019005825A2 true BR112019005825A2 (pt) | 2019-06-11 |
Family
ID=57539741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019005825-7A BR112019005825A2 (pt) | 2016-09-27 | 2017-09-06 | vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10982194B2 (https=) |
| EP (1) | EP3519565A1 (https=) |
| JP (2) | JP7258746B2 (https=) |
| KR (1) | KR102599401B1 (https=) |
| CN (1) | CN109890957A (https=) |
| AU (2) | AU2017337753B2 (https=) |
| BR (1) | BR112019005825A2 (https=) |
| CA (1) | CA3035104A1 (https=) |
| GB (1) | GB201616365D0 (https=) |
| RU (1) | RU2760521C2 (https=) |
| WO (1) | WO2018059896A1 (https=) |
| ZA (1) | ZA201902388B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907413D0 (en) * | 2019-05-24 | 2019-07-10 | Univ Helsinki | Viral vector |
| WO2020252039A1 (en) * | 2019-06-12 | 2020-12-17 | Biontech Us Inc. | Neoantigen compositions and uses thereof |
| US20220305099A1 (en) * | 2019-08-27 | 2022-09-29 | Turnstone Biologics Corp. | Methods for inducing an immune response against neoantigens |
| GB202013834D0 (en) * | 2020-09-03 | 2020-10-21 | Valo Therapeutics Oy | PeptiVAX therapy |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1257286C (zh) | 1998-08-27 | 2006-05-24 | 森泰莱昂公司 | 用于递送异源基因的定向腺病毒载体 |
| MXPA01005389A (es) * | 1998-11-30 | 2003-03-27 | Cytos Biotechnology Ag | Presentacion molecular ordenada de antigenos, metodos de preparacion y uso. |
| IL145899A0 (en) * | 1999-04-15 | 2002-07-25 | Pro Virus Inc | Treatment of neoplasms with viruses |
| CN100352921C (zh) | 1999-05-06 | 2007-12-05 | 威克福雷大学 | 用于鉴定引起免疫反应的抗原的组合物和方法 |
| CN101024842A (zh) * | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| GB0203285D0 (en) * | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| WO2004000220A2 (en) | 2002-06-21 | 2003-12-31 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
| US20070243170A1 (en) * | 2002-10-07 | 2007-10-18 | The University Of Chicago | Targeting of Herpes Simplex Virus to Specific Receptors |
| AU2004224761A1 (en) * | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
| HRP20120845T1 (hr) * | 2003-07-02 | 2012-11-30 | Innate Pharma | Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju |
| WO2005060541A2 (en) | 2003-12-01 | 2005-07-07 | Wisconsin Alumni Research Foundation | Peptides and methods for inducing cellular resistance to infection |
| KR101157694B1 (ko) * | 2003-12-17 | 2012-06-20 | 와이어쓰 엘엘씨 | 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법 |
| EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| JP2008136381A (ja) * | 2006-11-30 | 2008-06-19 | Japan Health Science Foundation | 改変型アデノウイルスベクター及びその作製方法 |
| WO2009117656A2 (en) | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| NO2700405T3 (https=) * | 2008-05-29 | 2018-09-01 | ||
| EP2349296B1 (en) * | 2008-08-21 | 2017-04-05 | Ottawa Hospital Research Institute | Engineered synergistic oncolytic viral symbiosis |
| ES2335077B1 (es) | 2008-12-30 | 2011-02-02 | Instituto Aragones De Ciencias De La Salud | Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores. |
| US8609392B2 (en) * | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
| US20130243731A1 (en) | 2010-09-24 | 2013-09-19 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| US20140140962A1 (en) | 2011-04-29 | 2014-05-22 | The Research Foundation Of State University Of New York | Viruses modified with unnatural moieties and methods of use thereof |
| US20140349944A1 (en) * | 2013-05-23 | 2014-11-27 | Musc Foundation For Research Development | Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases |
| RS65104B1 (sr) | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
| BR112016009465A8 (pt) * | 2013-10-28 | 2018-01-30 | Univ Pittsburgh Commonwealth Sys Higher Education | vetor de hsv oncolítico. |
| US10799568B2 (en) | 2014-05-19 | 2020-10-13 | Valo Therapeutics Oy | Modified adenoviruses for cancer vaccines development |
-
2016
- 2016-09-27 GB GBGB1616365.1A patent/GB201616365D0/en not_active Ceased
-
2017
- 2017-09-06 WO PCT/EP2017/072366 patent/WO2018059896A1/en not_active Ceased
- 2017-09-06 KR KR1020197012062A patent/KR102599401B1/ko active Active
- 2017-09-06 CA CA3035104A patent/CA3035104A1/en active Pending
- 2017-09-06 BR BR112019005825-7A patent/BR112019005825A2/pt not_active Application Discontinuation
- 2017-09-06 JP JP2019515292A patent/JP7258746B2/ja active Active
- 2017-09-06 US US16/337,220 patent/US10982194B2/en active Active
- 2017-09-06 CN CN201780056649.7A patent/CN109890957A/zh active Pending
- 2017-09-06 EP EP17765150.2A patent/EP3519565A1/en active Pending
- 2017-09-06 RU RU2019110407A patent/RU2760521C2/ru active
- 2017-09-06 AU AU2017337753A patent/AU2017337753B2/en active Active
-
2019
- 2019-04-15 ZA ZA2019/02388A patent/ZA201902388B/en unknown
-
2022
- 2022-12-09 JP JP2022197406A patent/JP2023029997A/ja active Pending
-
2023
- 2023-09-29 AU AU2023237201A patent/AU2023237201B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ751251A (en) | 2025-03-28 |
| AU2017337753A1 (en) | 2019-03-21 |
| JP2019532631A (ja) | 2019-11-14 |
| JP2023029997A (ja) | 2023-03-07 |
| KR102599401B1 (ko) | 2023-11-06 |
| US10982194B2 (en) | 2021-04-20 |
| AU2023237201A1 (en) | 2023-12-14 |
| AU2017337753B2 (en) | 2023-09-28 |
| US20200010811A1 (en) | 2020-01-09 |
| RU2019110407A (ru) | 2020-10-29 |
| EP3519565A1 (en) | 2019-08-07 |
| RU2760521C2 (ru) | 2021-11-26 |
| GB201616365D0 (en) | 2016-11-09 |
| JP7258746B2 (ja) | 2023-04-17 |
| ZA201902388B (en) | 2020-10-28 |
| WO2018059896A1 (en) | 2018-04-05 |
| AU2023237201B2 (en) | 2025-06-05 |
| CN109890957A (zh) | 2019-06-14 |
| CA3035104A1 (en) | 2018-04-05 |
| RU2019110407A3 (https=) | 2021-05-13 |
| KR20190053260A (ko) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| CY1123845T1 (el) | Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
| CR20200140A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CY1122038T1 (el) | Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4 | |
| CL2019000277A1 (es) | Tratamiento conjunto contra el cáncer. | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| EP4403229A3 (en) | Expression of pten-long with oncolytic viruses | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
| BR112019005305A2 (pt) | compostos espirocíclicos | |
| MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| PH12016500137A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
| MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
| BR112017012859A2 (pt) | fosforamidatos para o tratamento do vírus da hepatite b | |
| WO2018083220A3 (en) | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines | |
| IL263979A (en) | Enveloped virus resistant to complement inactivation | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| EP4599893A3 (en) | Cg0070 for treating bcg resistant bladder carcinoma in situ | |
| BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
| BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| BR112019005825A2 (pt) | vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer | |
| EA201792058A1 (ru) | Виротерапия комбинацией антител |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: VALO THERAPEUTICS OY (FI) |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |